We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
- Authors
Grünwald, Viktor; Powles, Thomas; Masatoshi Eto; Kopyltsov, Evgeny; Sun Young Rha; Porta, Camillo; Motzer, Robert; Hutson, Thomas E.; Méndez-Vidal, María José; Sung-Hoo Hong; Winquist, Eric; Goh, Jeffrey C.; Maroto, Pablo; Buchler, Tomas; Takagi, Toshio; Burgents, Joseph E.; Perini, Rodolfo; Cixin He; Okpara, Chinyere E.; McKenzie, Jodi
- Abstract
This document is a corrigendum for an article titled "Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms." The corrigendum acknowledges errors in the legend for Figure 3 and Supplementary Table 1, which resulted in the omission of clarification regarding the calculation of objective response rates and complete response rates. The corrected legend and figures have been provided. Additionally, a correction has been made to a sentence in Section 3.2.3 regarding complete response rates. The authors apologize for the errors and state that they do not affect the scientific conclusions of the article.
- Subjects
RENAL cell carcinoma; SUNITINIB; MEDICAL sciences
- Publication
Frontiers in Oncology, 2024, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2023.1343027